Summary Thirty-three patients with borderline leprosy who had developed recent (less than 6 months duration) loss of nerve fu nction were treated with a semi-standardized course of corticosteroids, the average initial dose was 25 mg prednisolone daily, and the average duration was 5 months. Treatment was unsupervised and no patient was admitted to hospital. The results were assessed by tests of voluntary muscle power and of sensory fu nction, of the 57 nerves studied, 38 showed marked improvement and none got worse. There were no serious side-effects. Patients were taught exercises to prevent deformity, and residual muscle weakness did not progress to contractures. Corticosteroid treatment is safe enough, and confers sufficient benefit to be used in standard dosage under field conditions. It is common experience that a patient will present himself for treatment because of recent nerve damage (motor or sensory) or signs of incipient nerve damage ('aches and pains' or paraesthesiae), commonly of only a few months duration. In such cases there is a good prospect of improvement if effective treatment for neuritis is instituted promptly. This is even more true of those patients who develop nerve damage during the first years of chemotherapy.
It is common experience that a patient will present himself for treatment because of recent nerve damage (motor or sensory) or signs of incipient nerve damage ('aches and pains' or paraesthesiae), commonly of only a few months duration. In such cases there is a good prospect of improvement if effective treatment for neuritis is instituted promptly. This is even more true of those patients who develop nerve damage during the first years of chemotherapy.
In patients with borderline leprosy the nerve damage is caused by the cell mediated immune response to antigens of Mycobacterium leprae, and many patients with recent nerve damage show signs of actual or incipient Type I lepra reaction (reversal reaction) in their skin lesions. The natural history of this reaction (rapid onset, gradual subsidence over a period of months) suggests a logical pattern of steroid treatment. 1 But no 'standard course' has yet won general acceptance. It is often difficult to treat patients with nerve damage under field conditions, indeed, there is a tendency to insist on hospitalization fo r steroid treatment. But patients will probably refuse unless they have severe painful neuritis. Moreover 0305-75 1 8/85/056127+08 SOLOO © British Leprosy Relief Association there are often few beds available and no effective referral system. Jfthe beds are in a general medical unit, hospital staff will usually have little knowledge or interest in the management of leprosy neuritis.
It is not surprising that field ·staff, unauthorized to give effective treatment fo r neuritis and often unable to refer patients fo r such treatment, may consider it unimportant to look fo r signs of nerve damage. In this situation it would be helpful if there was known to be a standard course of corticosteroids, which was effective in improving most patients, and was seldom harmful when used under field conditions. This paper reports the results of an out-patient study using a semi-standardized course of prednisolone to treat patients with recent nerve damage. We hope it will contribute towards defining a standard course fo r field use.
Patients and methods
The study included all borderline leprosy patients registered during 1982 fo r treatment in Dhoolpet Leprosy Research Centre, Hyderabad, who had, by their history, developed signs of nerve damage within the previous 6 months. About half of them had received some previous treatment fo r leprosy, the rest were untreated.
INITIAL ASSESS MENT
This included clinical examination of the skin lesions and palpation of nerves. Slit skin smears for acid fa st bacilli were taken in all cases, and skin biopsy to confirm the clinical classification in about half the patients.
Nerve damage was assessed by tests of voluntary muscle power (YMT) of muscles supplied by the facial, ulnar, median and lateral popliteal nerves.2 Sensory tests (ST) in areas supplied by affected nerves were performed using graded nylon bristles;) tests fo r protective sensation (indentation of the skin by a ball-point pen tip) were also undertaken.
The YMT results for the ulnar nerve were scored by adding the figures (0-5 scale) fo r the 2 muscles tested, which were abductor digiti minimi and I st dorsal interosseous. Other nerves, where only one muscle or group was tested, were scored by doubling the YMT figure. Thus the scores fo r all nerves could be directly compared.
TREAT MENT
All patients received dapsone 50-100 mg daily as anti-leprosy chemotherapy. Treatment for neuritis was with prednisolone. The average initial dose was 25 mg daily; this was normally reduced by 5 mg daily per month. However, dosage was adjusted fo r body weight, and also fo r severity of neuritis (the more severe the neuritis the higher the initial steroid dosage). Patients were advised to take the fu ll daily dosage of both dapsone and prednisolone as a single morning dose. All treatment was unsupervised, on an out-patient basis.
HEAL TH EDUCA nON
This was undertaken by the doctor who saw the patient, and occupied 30 per cent or more of an average consultation. Points covered included:
Appropriate active and passive exercises for affected muscles. It was emphasised that treatment might prevent permanent weakness and sensory loss, but exercises were needed to strengthen muscles and prevent stiffness and contractures .. 2 Education on the risks of anaesthesia (if it was present) and the principles of hand and fo ot care. 3 Encouragement to take tablets regularly, and warning that prednisolone was dangerous if not taken according to instructions.
ASSESSMENTS DURING TREATMENT
Most patients were seen every 1 -2 months during the period of steroid treatment, and every 2-6 months thereafter. Routine examination included palpation fo r nerve tenderness, and VMT and ST to assess the degree of improvement. Patients were asked to demonstrate how they did their exercises at home. Note was made of any symptoms that might be due to drug toxicity. Health ed ucation was continued according to the patients needs.
In most patients the steroid dosage was reduced month by month. However, if there was persistent or recurrent nerve pain or tenderness, or if fu nction deteriorated, the steroid dosage was prolonged and/or temporarily increased .
Results
Forty-five patients were included in the trial, of whom 33 (classified clinically as BT-24, BB-2, BL-7) completed their steroid treatment and were available for fo llow up. Some had more than one affected nerve; the number of damaged nerves was 57 (BT-37, BB-5, BL-15). In about 80% of cases the final fo llow up assessment was more than 6 months after steroid treatment had been discon tinued (Table I) .
A 'good' end result was defined as VMT power of 4 or 5 (i.e., a nerve score of 8-10). Table 2 shows the initial steroid dosage, number of patients, and results of treatment. About three-quarters of the nerves showed a good result. The degree of improvement (difference between initial and final scores) was 6 or more in two-thirds of the nerves ( Table 3) ; none of them got worse. BB and BL nerves did as well as BT nerves.
The sensory status at follow up is shown in Table 4 . It was normal or near normal in half the patients; only a quarter of them had lost protective sensation.
There were fe w toxic effects which could be attributed to the treatment. A few patients complained of epigastric pain which responded to antacids and reduced spice in the diet. A fe w developed infections of the hands or fe et which were controlled by antibiotics. None developed signs of progressive tuberculosis, severe intestinal parasite infestation, diabetes or hypertension. The course was too short for osteoporosis to be a problem, and no patients complained of symptoms of adrenal insufficiency on stopping steroid treatment. 
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Nerve damage is not the only cause of deformity. Failure to do simple exercises leads to unnecessary stiffness and contracture fo rmation; fa ilure of reasonable hand and fo ot care will allow injuries and infections to cause fu rther tissue loss and scarring. But the deformities which are commonly seen in patients who have been diagnosed reasonably early and treated (but without steroids) reasonably regularly indicate the need fo r more intensive measures to recognize and treat recent nerve damage as quickly as possible. Not all improvement of function is attributable to recovery of nerve function. Motor units of a partially denervated muscle can hypertrophy, and sensory damage can to some extent recover by filling in from neighbouring nerve territories. Thus the management of a patient with nerve damage is not just a matter of prescribing corticosteroids; health education, centred round the need for regular exercises and hand and fo ot care is of comparable importance.
Nevertheless, steroids offer an increased prospect of reversing nerve damage and so obviating the need for a lifetime of burdensome exercises and precautions.
However, steroids are dangerous if misused, and in any case are only part of the overall management of neuritis (albeit the part which makes the rest really worthwhile). There is scope fo r discussion of what grades of worker could be authorized to use steroids. But effective treatment of nerve damage depends on steroids being available to use in defined courses by workers who have regular patient contact.
The present study was based on a 'city centre' clinic, and patients, though managed as out-patients, were always seen by a doctor. We did not aim to demonstrate the field use of steroids. But the study has shown 3 important preliminary points:
In the dosage we employed, steroids were safe for out-patient use. We took no special steps, fo r instance, to exclude tuberculosis in patients who looked well and had no cough. We did not advise patients to avoid work, even ifit was manual and involved the risk of injuries and infections. Patients were warned that the tablets were dangerous in high dosage; we seldom fo und them taking too many, and were not pestered to continue prescribing them after the end of the course of treatment. On the other hand, the fe w patients who developed rec urrent painful neuritis knew that they would be prescribed additional dosage to control their symptoms, and would not have to try to buy extra tablets for themselves elsewhere. 2 In the dosage we employed, steroids were effective. Most patients showed improvement, and most ended up with useful hands and feet. Even those with persistent weakness usually did not develop contracture deformities, and so avoided the stigma of being obvious 'lepers'. Although much of the benefit must be attributed to the steroid treatment, the health education, which was an integral part of the management, played an important role in its success. . 3 Our patients were not angels. They were sometimes late fo r appointments, and no doubt sometimes fo rgot to take their tablets. Results such as ours can reasonably be expected in out-patients with unsupervised treatment.
The results of a similar studt have been reported.
This used a longer course of prednisolone, starting at higher dosage (40 mg daily for 2 weeks, 30 mg daily fo r 2 weeks, then 25-20-15-10-5 mg daily, red ucing the dosage monthly. The whole course lasted fo r 6 months, and patients were admitted to hospital fo r months I and 2. The results of their study were much the same as ours (see Table 5 , where the two studies are compared using the scoring system4 fo r VMT's). This suggests that the results of both studies are about the best that can be obtained, and that lower dosage than we used, which would be more suitable fo r the field use of steroids, might still give worthwhile benefits.
We did not use a rigid dosage schedule in this study, and more work will be needed to define a standard course. The patients attending Dhoolpet Leprosy Research Centre are self-selected, and probably have more severe disease, and so * Only nerves which showed improvement are included in these groups. YMT score is as in Touw el al. 4 probably risk more severe and prolonged neuritis, than patients in a normal field programme. It is therefore probable that a standard dosage schedule will start at a lower dosage than we usually used . But if the treatment is to do more good than harm the dosage must be high enough, and the course long enough, to relieve the symptoms of neuritis in most cases. A course which commonly fa ils to do this is unlikely to do any good at all.
Further studies are needed to define a course of steroids for field use which adequately balances benefits and toxicity. But in the meantime consideration should be given to the training needs of those who use steroids to treat neuritis. We suggest the fo llowing. The doctor or field worker using steroids to treat neuritis must know:
How to diagnose borderline leprosy (BT to BL on the Ridley-Jopling scale) and distinguish it fr om lepromatous. 2 How to palpate nerves and recognize when they are enlarged and/or tender. 3 How to test fo r protective sensation of the hands and fe et. 4 How to do VMT's of the abductor digiti minimi, abductor pollicis brevis, and dorsiflexors of the fo ot. 5 How to teach hand and fo ot care, particularly the treatment of minor injuries and recognition of infection at an early stage. 6 How to teach maintenance exercises for the hands, particularly to prevent finger and thumb web contractures and strengthen the extensor muscles of the fingers. 7 The symptoms and signs of damage to nerves commonly damaged in leprosy, including sensory loss, and how to obtain accurate information about them from the patient. 8 The standard treatment regimen used to treat parients with evidence of recent nerve damage.
9 The signs of steroid toxicity and how to treat patients who develop them. 10 How to recognize inadequate response to treatment.
II
How and where to refer patients in whom treatment appears to be ineffective.
